Study on Early Diagnosis and Precision Treatment of Primary vitreoretinal Lymphoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037570

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary vitreoretinal lymphoma

Interventions

1:Intravitreous injection of 200ug MTX

2:Intravitreous injection of 400ug MTX

3:none

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-80 years old; 2) The subject has a central nervous system or eye damage as the first symptom; 3) Collect intraocular samples during diagnostic vitrectomy, and confirm the diagnosis of PVRL by cell immunochemical staining and flow cytometry; 4) Strict physical examination and auxiliary examinations did not reveal any involvement of lymphoid hematopoietic tissue or other systems throughout the body; 5) The subject reads and fully understands the patient instructions, and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Female during pregnancy or lactation; 2) No laboratory test is clearly diagnosed as lymphoma; 3) The tumor involves parts other than the central nervous system; 4) Severe cardiac insufficiency, liver insufficiency or renal insufficiency; 5) Those who recently participated in other drug clinical trials.

Design outcomes

Primary

Measure	Time frame
complete reponse rate, CRR;Recurrence rate, CR;	—

Countries

China

Contacts

Public ContactZhang Yu

Huashan Hospital Affiliated to Fudan University

beautyashley@126.com+86 18930600370

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026